21 May 2013
Keywords: USA, FTC, Lundbeck, NeoProfen, Eli Lilly, Zyprexa, Overpricing, Class action
Article | 13 September 2010
The US Federal District Court has ruled in favor of Danish drugmaker H Lundbeck (LUND: DC) and found no violation ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 September 2010
20 May 2013
© 2013 thepharmaletter.com